| Code | CSB-RA004902MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to PHST-001, targeting CD24, a small heavily glycosylated mucin-like cell surface protein. CD24 functions as a co-stimulatory molecule in immune cell regulation and plays a critical role in cell adhesion, differentiation, and survival signaling. The protein is expressed on various immune cells, including B cells and neutrophils, as well as on numerous cancer types where it serves as a marker of cancer stem cells. CD24 has been implicated in tumor progression, metastasis, and immune evasion, making it a significant target in oncology research. Elevated CD24 expression correlates with poor prognosis in multiple malignancies, including breast, ovarian, pancreatic, and colorectal cancers.
PHST-001 represents an important research tool for investigating CD24-mediated pathways in cancer biology and immunology. This biosimilar antibody enables researchers to study CD24's role in tumor microenvironment modulation, cancer stem cell biology, and immune checkpoint mechanisms. It supports investigations into therapeutic strategies targeting CD24-positive malignancies and provides valuable insights into immune-oncology applications.
There are currently no reviews for this product.